Can I read Correction to “Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study” [The Lancet Regional Health – Americas 2022; 16: 100366] on EtoBox?

Correction to “Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study” [The Lancet Regional Health – Americas 2022; 16: 100366] by Más-Bermejo, Pedro I. (author);Dickinson-Meneses, Félix O. (author);Almenares-Rodríguez, Kenia (author);Sánchez-Valdés, Lizet (author);Guinovart-Díaz, Raúl (author);Vidal-Ledo, María (author);Galbán-García, Enrique (author);Olivera-Nodarse, Yadira (author);Morgado-Vega, Isabel (author);Dueñas-Carrera, Santiago (author);Pujol, Merardo (author);Hernández-Bernal, Francisco (author);Limonta-Fernández, Miladys (author);Guillén-Nieto, Gerardo (author);Muzio-González, Verena L. (author);Ayala-Ávila, Marta (author) is a Medicine article available to read on EtoBox.

What is Correction to “Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study” [The Lancet Regional Health – Americas 2022; 16: 100366] about?

Background: COVID-19 vaccines have proven safe and efficacious in reducing severe illness and death. Cuban protein subunit vaccine Abdala has shown safety, tolerability and efficacy (92.3% [95% CI: 85.7-95.8]) against SARS-CoV-2 in clinical trials. This study aimed to estimate Abdala's real-world vaccine effectiveness (VE). Methods: This retrospective cohort study in Havana analyzed Cuban Ministry of Public Health databases (May 12- August 31, 2021) to assess VE in preventing severe illness and death from COVID-19 (primary outcomes). Cox models accounting for time-varying vaccination status and adjusting by demographics were used to estimate hazard ratios. A subgroup analysis by age group and a sensitivity analysis including a subgroup of tested persons (qRT-PCR) were conducted. Daily cases and deaths were modelled accounting for different VE. Findings: The study included 1,355,638 persons (Mean age: 49.5 years [SD: 18.2]; 704,932 female [52.0%]; ethnicity data unavailable): 1,324,205 vaccinated (partially/fully) and 31,433 unvaccinated. Estimated VE against severe illness was 93.3% (95% CI: 92.1-94.3) in partially vaccinated and 98.2% (95% CI: 97.9-98.5) in fully vaccinated and ag

Who reads Correction to “Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study” [The Lancet Regional Health – Americas 2022; 16: 100366]?

Author

Más-Bermejo, Pedro I. (author);Dickinson-Meneses, Félix O. (author);Almenares-Rodríguez, Kenia (author);Sánchez-Valdés, Lizet (author);Guinovart-Díaz, Raúl (author);Vidal-Ledo, María (author);Galbán-García, Enrique (author);Olivera-Nodarse, Yadira (author);Morgado-Vega, Isabel (author);Dueñas-Carrera, Santiago (author);Pujol, Merardo (author);Hernández-Bernal, Francisco (author);Limonta-Fernández, Miladys (author);Guillén-Nieto, Gerardo (author);Muzio-González, Verena L. (author);Ayala-Ávila, Marta (author)

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)